Optiscan Improving Cancer Outcomes with Digital Pathology & Precision Surgery, page-12

(1) Optiscan’s current share price is not reflective of its actual value.

Quite simply because about 70% of the shares are held by the top twenty shareholders and those shares are not on the market. Up to an estimated 500 holders may hold more than 95% of the shares. And 95% of those 500 holders appear to hold more than 100,000 shares. The picture will become much clearer inthe June 2024 Annual Report.

Current trading consists of two types of transactions:

(1) large shareholders slowly accumulating more shares under the radar, and

(2) day traders.

The only exception was the recent sale of around 1,266,000 shares by necessity. The circumstances were indicated by a recent poster.

The real question Spritzer should be asking is:

To purchase 5% of Optiscanshares on the market today, what would be the average cost of each share?

We can only speculate on what the answer is. Be it 50 cents, 75 cents, $1 or more. Whatever the amount, it is much higher than the current share price.

(2) Update – The Paula Fox Melanoma and Cancer Centre in Melbourne was officially opened today by the Prime Minister of AustraliaAnthony Albanese and Premier of Victoria Jacinta Allan.

The new $152.4 million facilitywill deliver lifesaving clinical trials, research and care.

It is ideally suited to use Optiscan’s technology.

Significantly, today the Prime Minister announced:

The government is investing $12 million through the 2024–25 Budget,to purchase and install a Quadra Positron Emission Tomography/ComputedTomography (PET/CT) Molecular Imaging scanner. The Victorian Government and The Alfred Foundation will match thisfunding. The scanner will support anadditional 2,600 scans annually, more than doubling current capacity to 5,000scans.

It is estimated around 165,000 cases of cancer are diagnosed eachyear in Australia and sadly more than 50,000 people will lose their lives tocancer.

Moreover, the federal government of Australia is investing more than $2.8 billion over the next four years to improve canceroutcomes, excluding the cost of Medicare services and pharmaceuticals.

InVivage’stiming is impeccable.